<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05107778</url>
  </required_header>
  <id_info>
    <org_study_id>ASC42-201</org_study_id>
    <nct_id>NCT05107778</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV</brief_title>
  <official_title>A Phase II Multi-center, Randomized, Single-blind, Placebo-controlled to Evaluate Safety and Efficacy of ASC42 Tablets in Combination With Entecavir and Pegylated Interferon α-2a in Subjects With Chronic Hepatitis B Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascletis Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascletis Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase2, randomized, single-blind, placebo controlled and multi-center study in&#xD;
      adults with chronic hepatitis B virus. The study is aimed at evaluating efficacy and safety&#xD;
      of ASC42 in combination with entecavir and pegylated interferon α-2a in subjects with chronic&#xD;
      hepatitis B virus.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 17, 2021</start_date>
  <completion_date type="Anticipated">February 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 8, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum HBsAg change compared with baseline</measure>
    <time_frame>Week 12 of intervention\Week 24 of follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum HBV pgRNA change compared with baseline</measure>
    <time_frame>Week 12 of intervention\Week 24 of follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum HBsAg change compared with baseline</measure>
    <time_frame>Week 2, 4 ,8 of intervention\Week 4,12 of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum HBV pgRNA change compared with baseline</measure>
    <time_frame>Week 2, 4 ,8 of intervention\Week 4,12 of follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Queue ASC42 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASC42 10mg, ih PEG-IFN α-2a and ETV for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Queue ASC42 15mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASC42 15mg , ih PEG-IFN α-2a and ETV for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Queue Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, ih PEG-IFN α-2a and ETV for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASC42 10mg</intervention_name>
    <description>ASC42 10mg orally once daily;</description>
    <arm_group_label>Queue ASC42 10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASC42 15mg</intervention_name>
    <description>ASC42 15mg orally once daily.</description>
    <arm_group_label>Queue ASC42 15mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ih PEG-IFN α-2a</intervention_name>
    <description>ih PEG-IFN α-2a 180μg subcutaneous injection once a week.</description>
    <arm_group_label>Queue ASC42 10mg</arm_group_label>
    <arm_group_label>Queue ASC42 15mg</arm_group_label>
    <arm_group_label>Queue Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Entecavir 0.5 mg orally once daily.</description>
    <arm_group_label>Queue ASC42 10mg</arm_group_label>
    <arm_group_label>Queue ASC42 15mg</arm_group_label>
    <arm_group_label>Queue Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo orally once daily.</description>
    <arm_group_label>Queue Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-65 years old (including 18 and 65 years old);&#xD;
&#xD;
          -  Chronic HBV infection confirmed by serological, etiological and clinical diagnosis&#xD;
             (HBsAg positive for more than 6 months);&#xD;
&#xD;
          -  HBV-DNA negative after nucleoside (acid) treatment;&#xD;
&#xD;
          -  Laboratory test values meet the following requirements :&#xD;
&#xD;
               -  Liver function : AST, ALT ≤ 3×ULN; serum total bilirubin≤2×ULN; direct&#xD;
                  bilirubin≤1.5×ULN; serum albumin≥35 g/L (blood collection is not within 2 weeks&#xD;
                  before transfusion of albumin);&#xD;
&#xD;
               -  Hematology: white blood cell count&gt;3.0×109/L, ANC&gt;1.5×109/L; platelet&gt;1×ULN;&#xD;
                  hemoglobin 120g/L. (No blood transfusion (including transfusion of red blood&#xD;
                  cells and platelets) and EPO, TPO, leukocyte-stimulating factor were required&#xD;
                  within 2 weeks before blood collection) ;&#xD;
&#xD;
               -  Renal function: serum creatinine≤1×ULN;&#xD;
&#xD;
               -  Thyroid function: TSH and T4 in normal range or thyroid function can be&#xD;
                  completely controlled ;&#xD;
&#xD;
               -  Determination of serum immunoglobulin : IgM≤ULN;&#xD;
&#xD;
               -  Coagulation function: International normalized ratio: INR≤1×ULN;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic HBV with unexplained portal hypertension;&#xD;
&#xD;
          -  Subjects with liver cancer or serum AFP &gt;1×ULN;&#xD;
&#xD;
          -  Previously received FXR therapy;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jinlin Hou, Master</last_name>
    <phone>+86-13802727354</phone>
    <email>jlhousmu@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xieer Liang, Doctor</last_name>
    <phone>+86-18620087783</phone>
    <email>freeliang@163.com</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B, Chronic</keyword>
  <keyword>ASC42</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

